Duration of Raynaud's phenomenon is negatively correlated with serum levels of interleukin 10 (IL-10), soluble receptor of interleukin 2 (sIL2R), and sFas in systemic sclerosis patients

Medical Science Monitor

Volumn 10, Issue 5, 2004, Pages

  Dzlankowska Bartkowlak, Bozena ^a   Zalewka, Anna ^a   Sysa Jȩdrzejowska, Anna ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Raynaud's phenomenon duration; Systemic sclerosis

Indexed keywords

FAS ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; BLOOD LEVEL; BLOOD VESSEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE DURATION; DISEASE MARKER; DISEASE SEVERITY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PATHOGENESIS; RAYNAUD PHENOMENON; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; VASOMOTOR DISORDER;

ANTIGENS, CD95; CELL DIVISION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROSIS; HUMANS; INTERLEUKIN-10; INTERLEUKIN-2; RAYNAUD DISEASE; RECEPTORS, INTERLEUKIN-2; SCLERODERMA, SYSTEMIC; TIME FACTORS;

EID: 2942726423     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Fimiani C: Systemic sclerosis: a woman disease. Mod Asp Immunobiol, 2001; 1: 233-37
2. Kahaleh MB, Yin TG: The molecular mechanism of endothelial cell injury in scleroderma (SSc): identification of granzyme-1 (product of cytolytic T cells) in SSc sera. Arthritis Rheum, 1990; 33: 67-71
3. Kazandijan S, Bruneval P, Fissinger JN et al: Active proliferation of teleangiectases in skin of patients with systemic sclerosis (PSS). Arch Dermatol Res, 1998; 279: 8-12
4. Kahaleh MB, Yin T: Enchanced expression of high-affinity interleukin-2 receptors in scleroderma: possible role for IL-6. Clin Immunol Immunopathol, 1992; 1: 97-102
5. Veale DJ, Kirk G, McLaren M et al: Clinical implications of soluble intercellular adhesion molecule-1 levels in systemic sclerosis. Br J Rheumatol, 1998; 37: 1227-28
6. Rudnicka L: Twardzina ukŁadowa. Terapia, 1995; 6: 17-19
7. Whire B: Parhogenesis: Immune aspects. In PJ Clements, DE Furst, editors. Systemic sclerosis. Williams & Wilkins. Baltimore, Maryland, USA 1996: 229-50
8. Kantor TV, Friberg D, Medsger TA et al: Cytokine production and serum levels in systemic sclerosis. Clin Immunol Immunopathol, 1992; 3: 278-85
9. Mittag M, Beckheinrich P, Haustein UF: Systemic sclerosis-related Raynaud's phenomenon: effects of Illoprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels. Acta Derm Venereol, 2001; 81: 294-97
10. Majewski S, Skopińska-Rozewska E, Jabłonska S et al: Modulatory effect of sera from scleroderma patients on lymphocyte-induced angiogenesis. Arthritis Rheum, 1985; 28: 1133-37
11. Distiel O, del Rosso A, Giacomelli R et al: Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res, 2002; 4: R11
12. Szpringer E, Lutnicki K: Znaczenie apoptozy w wybranych chorobach w dermatologii. Nowa Medycyna, 2002; 116(3): 24-32
13. LeRoy EC: Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am, 1996; 22: 675-94
14. Jakóbisiak M: Immunologia. Wydawnictwo Naukowe PWN. Warszawa, 1995; 499-528
15. Kikuchi K, Kubo M, Sato S et al: Serum tissue inhibitor of metalloproteinases in patients with systemic sclerosis. J Am Acad Dermatol, 1995; 33: 973-78
16. Yazawa N, Kikuchi K, Ihn H et al: Serum levels of tissue inhibitor of metalloproteinases 2 in patients with systemic sclerosis. J Am Acad Dermatol, 2000; 42: 70-75
17. Black CM, Mc Whirter A, Harrison NK et al: Serum type III procollagen peptide concentrations in systemic sclerosis and Raynaud's phenomenon: relationship to disease activity and duration. Br J Rheumatol, 1989; 28: 98-103
18. Subcommittee for scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum, 1980; 23: 581-90
19. Fagundus DM, LeRoy EC: Cytokines and systemic sclerosis. Clin Dermatol, 1994; 12: 397-406
20. Majewski S, Wojas-Pelc A, Malejczyk M et al: Serum levels of soluble TNF alpha receptor type I and the severity of systemic sclerosis. Acta Derm Venereol (Stockh), 1999; 3: 207-10
21. Cush JJ, Splawski JB, Thomas R et al: Elevated interleukin 10 levels in patients with rheumatoid arthritis. Arthritis Rheum, 1995; 1: 96-104
22. Thompson-Snipes L, Dhar V, Bond MW et al: Interleukin-10 a novel stimulatory factor for mast cells and their progenitors. J Exp Med, 1991; 173: 507-10
23. Robak T: Interleukina-10 (IL-10). w Biologia i farmakologia cytokin, PWN Warszawa-łódź, 1995; 156-163
24. Reitamo S, Remitz A, Tamai K et al: Interleukin-10 modulates type I collagen and matrix metaloprotease gene expression in cultured human skin fibroblasts. J Clin Invest, 1994; 94: 2489
25. Ishida H, Muchamuel T, Sakaguchi S et al: Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/Wfl mice. J Exp Med, 1994; 179: 305-10
26. Waszczykowska E: Udział metabolizmu tlenowego w patogenezie tocznia rumieniowatego układowego. (In Polish) Rozprawa habilitacyjna, Łód́, 1998; 112-14
27. Clements PJ, Peter JB, Agopian MS et al: Elevated serum levels of soluble interleukin 2 receptor, interleukin 2 and neopterin in diffuse and limited scleroderma: effect of chlorambucil. J Rheumatol, 1990; 17: 908-10
28. Kahaleh MB: Soluble immunologic products in scleroderma sera. Clin Immunol Immunopathol, 1991; 58: 139-44
29. Sondergaard K, Stengaard-Pedersen K, Zachariae H et al: Soluble intercellular adhesion molecule (sICAM-1) and soluble interleukin-2 receptors (slL-2R) in scleroderma skin. Br J Rheumatol, 1998; 37: 304-10
30. Majewski S, Szymańska E: Patogeneza twardziny. Medipress Dermatol, 1996; 3: 2-7
31. Steen VD, Engel EE, Charley MR, Medsger TA: Soluble serum interleukin 2 receptors in patients with systemic sclerosis. J Rheumatol, 1996; 23: 646-49
32. Wendling D, Racadot E, Viel JF, Mercier M: Le dosage des recepteurs solubles de l'interleukine 2 n'a pas d'utilite au cours des rhumatismes inflammatories chroniques. Soluble interleukin -2 receptor assays are unhelpful in chronic inflammatory joint disease. Path Biol, 1992; 40: 895-98
33. Wojas-Pelc A, Majewski S, Malejczyk S, Jabłońska S: Parametry odczynowości komórkowej w twardzinie układowej - korelacje kliniczne. (In Polish) Przegl Dermatol, 1999; 86: 543-49
34. Gruschwitz MS, Albrecht M, Vieth G, Haustein UF: In situ expression and serum levels of tumor necrosis factor - (receptors in patients with early stages of systemic sclerosis. J Rheumatol, 1997; 24: 1936-43
35. Pepper MS: Manipulating angiogenesis. From basic science to the beside. Artherioscler Thromb Vasc Biol, 1997; 17: 605-19
36. Park CC, Morel JC, Amin MA et al: Evidence of IL-18 as a novel angiogenic mediator. J Immunol, 2001; 167: 1644-53
37. Jośko J, Gwóźdń B, J̧drzejowska- Szypułka H, Hendryk S: Vascular endothelial growth factor (VEGF) and its effect on angiogenesis. Med Sci Monit, 2000; 6: 1047-52
38. Carmeliet P, Ferreira V, Breier G et al: Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature, 1996; 380: 435-39
39. Robak E, Woźniacka A, Sysa-J̧drzejowska A et al: Circulating angiogenesis inhibitor endostatin and postive endothelial growth regulators in patients with systemic lupus erythematosus. Lupus, 2002; 11: 348-55
40. Szary J, Szala S: Endostatyna w terapii nowotworów. (In Polish) J Oncol, 2002; 52: 159-64
41. Sasaki T, Fukai N, Mann K et al: Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin. EMBO J, 1998; 17: 4249-56
42. Kim YM, Jang JW, Lee OH et al: Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase 2. Cancer Res, 2000; 60: 5410-13
43. Hebbar M, Peyrat JP, Hornez L et al: Increased concentrations of circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum, 2000; 43: 889-93
44. Nagashima M, Asano G, Yoshino S: Imbalance in production between vascular endothelial growth factor and endostatin in patients with rheumatoid arthritis. J Rheumatol, 2000; 27: 233942
45. Stassi G, Todaro M, Demaria R et al: Defective expression of CD95 (Fas/APO-1) molecule suggests apoptosis impairment of T and B cells in HLA-B8, DR3-positive individuals. Human Immunology, 1997; 55: 39-44
46. Cohen JJ: Overview: mechanisms of apoptosis. Immunology Today, 1993; 14(3): 126-30
47. Szpringer E, Lutnicki K: Znaczenie apoptozy w wybranych chorobach w dermatologii. (In Polish) Nowa Medycyna, 2002; 116: 24-32
48. Zhivotovsky B, Samali A, Gahm A et al: Caspase: their intracellular localization and translocation during apoptosis. Cell Death Differ, 1999; 8: 644-51
49. Wang S, Miura M, Yung YK et al: Murine caspase-11, an ICE-interacting protease, is essential for the activation of ICE, Cell, 1998; 92: 501-9
50. Nozawa K, Kayagaki N, Tokano Y et al: Soluble Fas (APO-1, CD95) and soluble Fas Ligand in rheumatic diseases. Arthritis Rheum, 1997; 40: 1126-29
51. Mountz JD, Wu J, Cheng J, Zhou T: Autoimmune disease: A problem of defective apoptosis. Arthritis Rheum, 1994; 37: 1415-20
52. Bianchi T, Bardazzi F, Patrizi A: Soluble Fas levels in patients with systemic sclerosis. Arch Dermatol Res, 2000; 292: 522-23
53. Majewski S, Skiendzielewska A, Makieła B et al: Serum levels of type III collagen aminopropeptide in patients with systemic scleroderma. Arch Dermatol Res, 1987; 279: 484-86
54. Guseva NG, Anikina NV, Myllyla R et al: Markers of collagen and basement membrane metabolism in sera of patients with progressive systemic sclerosis. Ann Rheum Dis, 1991; 50: 481-86
55. Heickendorff L, Zachariae H, Bjerring P et al: The use of serologic markers for collagen synthesis and degradation in systemic sclerosis. J Am Acad Dermatol, 1995; 32: 584-88
56. Wojas-Pelc A: Twardzina gł̧boka i choroby twardzinopodobne skóry z zaj̧ciem powi̧zi: badania ultrastrukturalne i immunohistochemiczne. (In Polish) Rozprawa habilitacyjna. Kraków, 2003
57. Sage H, Pritzl P, Bornstein P: Secrectory phenotype of endothelial cells in culture: comparison of aortic, venous capillary and corneal endothelium. Arteriosclerosis, 1981; 1: 427-42
58. Majewski S: Zmiany naczyniowe i zaburzenia immunologiczne w twardzinie. Ich wzajemne powi̧zanie. (In Polish) Rozprawa habilitacyjna. Warszawa, 1998